Regulatory Pathway for Intranasal CNS Drug Products at FDA
FDA lacks unified standards for proving drugs reach the brain via nasal delivery.
Cecilia Brandt-Kowalski
Section
Intranasal Delivery
3 stories in Intranasal Delivery.
Bioavailability Benchmarks for Intranasal Peptide Formulations
Plasma bioavailability fails to measure what intranasal brain-targeted peptides actually achieve.
Marcus Oyelaran
Nose-to-Brain Delivery for CNS-Active Peptides in Preclinical Models
Nasal delivery bypasses the blood-brain barrier for peptides that can't cross it systemically.
Priya Subramaniam